Abstract
Alemtuzumab for Immune-Related Myocarditis Myocarditis after the use of immune checkpoint inhibitors is a potentially fatal complication. Immune suppression with glucocorticoids is often effective ...
Cite
CITATION STYLE
APA
Esfahani, K., Buhlaiga, N., Thébault, P., Lapointe, R., Johnson, N. A., & Miller, W. H. (2019). Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy. New England Journal of Medicine, 380(24), 2375–2376. https://doi.org/10.1056/nejmc1903064
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free